RLMD
Price
$0.57
Change
-$0.03 (-5.00%)
Updated
Aug 8, 10:36 AM (EDT)
Capitalization
19.98M
90 days until earnings call
ZVRA
Price
$11.86
Change
-$0.27 (-2.23%)
Updated
Aug 8, 11:00 AM (EDT)
Capitalization
663.26M
4 days until earnings call
Interact to see
Advertisement

RLMD vs ZVRA

Header iconRLMD vs ZVRA Comparison
Open Charts RLMD vs ZVRABanner chart's image
Relmada Therapeutics
Price$0.57
Change-$0.03 (-5.00%)
Volume$205
Capitalization19.98M
Zevra Therapeutics
Price$11.86
Change-$0.27 (-2.23%)
Volume$200
Capitalization663.26M
RLMD vs ZVRA Comparison Chart in %
Loading...
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RLMD vs. ZVRA commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLMD is a Hold and ZVRA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (RLMD: $0.60 vs. ZVRA: $12.13)
Brand notoriety: RLMD and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLMD: 22% vs. ZVRA: 147%
Market capitalization -- RLMD: $19.98M vs. ZVRA: $663.26M
RLMD [@Biotechnology] is valued at $19.98M. ZVRA’s [@Biotechnology] market capitalization is $663.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLMD’s FA Score shows that 1 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • RLMD’s FA Score: 1 green, 4 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than RLMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLMD’s TA Score shows that 3 TA indicator(s) are bullish while ZVRA’s TA Score has 3 bullish TA indicator(s).

  • RLMD’s TA Score: 3 bullish, 6 bearish.
  • ZVRA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than RLMD.

Price Growth

RLMD (@Biotechnology) experienced а -3.29% price change this week, while ZVRA (@Biotechnology) price change was +9.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

RLMD is expected to report earnings on Nov 06, 2025.

ZVRA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZVRA($663M) has a higher market cap than RLMD($20M). ZVRA YTD gains are higher at: 45.444 vs. RLMD (15.750). ZVRA has higher annual earnings (EBITDA): -60.3M vs. RLMD (-79.12M). ZVRA has more cash in the bank: 62.6M vs. RLMD (27.1M). RLMD has less debt than ZVRA: RLMD (256K) vs ZVRA (61.8M). ZVRA has higher revenues than RLMD: ZVRA (40.6M) vs RLMD (0).
RLMDZVRARLMD / ZVRA
Capitalization20M663M3%
EBITDA-79.12M-60.3M131%
Gain YTD15.75045.44435%
P/E RatioN/AN/A-
Revenue040.6M-
Total Cash27.1M62.6M43%
Total Debt256K61.8M0%
FUNDAMENTALS RATINGS
RLMD vs ZVRA: Fundamental Ratings
RLMD
ZVRA
OUTLOOK RATING
1..100
7121
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
85
Overvalued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
4139
P/E GROWTH RATING
1..100
10027
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RLMD's Valuation (19) in the null industry is significantly better than the same rating for ZVRA (85). This means that RLMD’s stock grew significantly faster than ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (62) in the null industry is somewhat better than the same rating for RLMD (100). This means that ZVRA’s stock grew somewhat faster than RLMD’s over the last 12 months.

RLMD's SMR Rating (99) in the null industry is in the same range as ZVRA (100). This means that RLMD’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Price Growth Rating (39) in the null industry is in the same range as RLMD (41). This means that ZVRA’s stock grew similarly to RLMD’s over the last 12 months.

ZVRA's P/E Growth Rating (27) in the null industry is significantly better than the same rating for RLMD (100). This means that ZVRA’s stock grew significantly faster than RLMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RLMDZVRA
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 11 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
72%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CPODX57.71N/A
N/A
Morgan Stanley Insight I
RSPYX30.34N/A
N/A
Victory RS Partners Y
BGRFX81.67N/A
N/A
Baron Growth Retail
MAIJX19.29N/A
N/A
Morgan Stanley Inst Passport ovrs eq R6
MSDMX14.01N/A
N/A
Morgan Stanley Emerging Mkt ex China R6

RLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
+0.48%
SYRE - RLMD
36%
Loosely correlated
-4.51%
ENTO - RLMD
36%
Loosely correlated
-9.09%
PRTC - RLMD
31%
Poorly correlated
-1.70%
AVXL - RLMD
31%
Poorly correlated
+2.28%
ZVRA - RLMD
29%
Poorly correlated
+5.66%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with DNTH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then DNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+5.66%
DNTH - ZVRA
35%
Loosely correlated
-6.08%
COGT - ZVRA
33%
Loosely correlated
-0.82%
AXON - ZVRA
33%
Loosely correlated
+0.85%
GOSS - ZVRA
33%
Poorly correlated
-12.88%
VCYT - ZVRA
33%
Poorly correlated
+15.48%
More